(NASDAQ: DNLI) Denali Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Denali Therapeutics's revenue in 2025 is $0.On average, 8 Wall Street analysts forecast DNLI's revenue for 2025 to be $6,916,463,858, with the lowest DNLI revenue forecast at $322,378,168, and the highest DNLI revenue forecast at $18,151,923,875. On average, 12 Wall Street analysts forecast DNLI's revenue for 2026 to be $18,743,240,947, with the lowest DNLI revenue forecast at $3,679,903,223, and the highest DNLI revenue forecast at $40,163,672,843.
In 2027, DNLI is forecast to generate $41,853,689,563 in revenue, with the lowest revenue forecast at $16,626,436,193 and the highest revenue forecast at $113,400,150,986.